Presentations and Publications
Prior to August 2023, CervoMed was known as EIP Pharma, the name utilized in prior publications from the company.
September 2023 | CervoMed
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies
Neurology | Alam, et al.
April 2023 | CervoMed
Effects of the p38-Alpha Kinase Inhibitor Neflamapimod on the Basal Forebrain in Patients, Assessed by Structural MRI
AD/PD™ 2023 | Alam, et al.
December 2022 | CervoMed
LP102 Effects of the p38α kinase inhibitor neflamapimod on the basal forebrain, as assessed by structural MRI, in Alzheimer’s Disease
CTAD 2022 | Alam, et al
September 2022 | CervoMed
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration
Nature Communications | Jiang, et al.
November 2021 | CervoMed
OC5 – Effects of the oral p38α kinase inhibitor neflamapimod on motor function (gait) in patients with mild-to-moderate dementia with Lewy bodies (DLB)
CTAD 2021 | Alam, et al.
May 2021 | CervoMed
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
Alzheimer’s Research & Therapy | Prins, et al.
December 2020 | CervoMed
Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level
PLOSOne | Alam, et al.
September 2020 | EXTERNAL EXPERTS
Functions of p38 MAP Kinases in the Central Nervous System
Frontiers in Molecular Neuroscience | Asih, et al.
July 2020 | CervoMed
P38α MAPK Signaling—A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease
International Journal of Molecular Sciences | Alam, et al.
May 2020 | EXTERNAL EXPERTS
Neuronal deficiency of p38α‐MAPK ameliorates symptoms and pathology of APP or Tau‐transgenic Alzheimer’s mouse models
The FASEB Journal | Schnoder, et al.
May 2018 | EXTERNAL EXPERTS
Associations of MAP2K3 Gene Variants With Superior Memory in SuperAgers
Frontiers in Aging Neuroscience | Huentelman, et al.
December 2017 | EXTERNAL EXPERTS
Forecasting the Prevalence of Preclinical and Clinical Alzheimer’s Disease in the United States
Alzheimer’s & Dementia | Brookmeyer, et al.
March 2017 | EXTERNAL EXPERTS
Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer’s mouse model by controlling β-amyloid production
Scientific Reports | Colie, et al.
March 2017 | EXTERNAL EXPERTS
Aged Dominant Negative p38α MAPK Mice are Resistant to Age-Dependent Decline in Adult-Neurogenesis and Context Discrimination Fear Conditioning
Behavioural Brain Research | Cortez, et al.
January 2017 | EXTERNAL EXPERTS
Glucose Deﬁcit Triggers Tau Pathology and Synaptic Dysfunction in a Tauopathy Mouse Model
Translational Psychiatry | Lauretti, et al.
December 2016 | EXTERNAL EXPERTS
Selective Suppression of the α Isoform of p38 MAPK Rescues Late-Stage Tau Pathology
Alzheimer’s Research & Therapy | Maphis, et al.
November 2016 | CervoMed
Targeting Neuronal MAPK14/p38α Activity to Modulate Autophagy in the Alzheimer Disease Brain
Autophagy | Alam, et al.
December 2015 | EXTERNAL EXPERTS
Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1
Journal of Biological Chemistry | Schnoder, et al.
September 2015 | EXTERNAL EXPERTS
Synapse-Specific IL-1 Receptor Subunit Reconfiguration Augments Vulnerability to IL 1β in the Aged Hippocampus
Proceedings of the National Academy of Sciences of the United States of America | Prieto, et al.
December 2012 | EXTERNAL EXPERTS
p38α Mitogen-Activated Protein Kinase Depletion and Repression of Signal Transduction to Translation Machinery by miR-124 and -128 in Neurons
Molecular and Cellular Biology | Lawson, et al.